Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Bayer/Janssen’s bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.